Table 1. Characteristics of patients with subclinical and overt thyroid irAEs and comparisons to those without thyroid irAEs.
| Thyroid irAE (−) | Thyroid irAE (+) | ||||
|---|---|---|---|---|---|
| n = 133 | Subclinical | p | Overt | p | |
| n = 40 | n = 27 | ||||
| Age (years) | 67 (60–73) | 69 (58–75) | 0.701 | 67 (60–73) | 0.958 |
| Gender (n) | 0.420 | 0.022 | |||
| Male | 94 (70.7%) | 27 (67.5%) | 13 (48.2%) | ||
| Female | 39 (29.3%) | 13 (32.5%) | 14 (51.8%) | ||
| Primary sites (n) | 0.286 | 0.409 | |||
| Lung cancer | 77 (57.9%) | 29 (72.5%) | 12 (44.5%) | ||
| Malignant melanoma | 28 (21.05%) | 6 (15.0%) | 8 (29.6%) | ||
| Others | 28 (21.05%) | 5 (12.5%) | 7 (25.9%) | ||
| Results before nivolumab therapy | |||||
| Positive TPOAb (n) | 0 (tested in 7) (0.0%) | 1 (tested in 4) (25.0%) | NA | 3 (tested in 6) (50.0%) | NA |
| Positive TgAb (n) | 0 (tested in 7) (0.0%) | 1 (tested in 4) (25.0%) | NA | 5 (tested in 6) (83.3%) | NA |
| Thyroid uptake of FDG-PET (n) | 3 (tested in 71) (4.2%) | 1 (tested in 25) (4.0%) | 1.000 | 7 (tested in 15) (46.7%) | < 0.001 |
| Thyroid function | |||||
| free T3 (pg/mL) | 2.57 (2.20–2.89) | 2.49 (2.25–2.83) | 0.684 | 2.59 (2.18–2.82) | 0.895 |
| free T4 (ng/dL) | 1.250 (1.100–1.380) | 1.270 (1.100–1.360) | 0.979 | 1.160 (0.946–1.350) | 0.184 |
| TSH (μIU/mL) | 2.260 (1.353–4.443) | 2.580 (0.935–4.430) | 0.940 | 3.620 (1.870–7.310) | 0.014 |
Data of continuous variable were expressed as medians (interquartile range). Statistical analyses were performed against thyroid irAE (–) group.
We did not perform statistical analysis of TPOAb and TgAb results because the numbers of missing values were large.
n: number of subjects, irAE: immune-related adverse event, NA: not available